Open mbrush opened 5 years ago
Some examples of terms used to describe experimental impact:
CIViC Oncogenic mechanism terms describing functional impact: see https://github.com/ga4gh-gks/variant-annotation-model/issues/28, and the example here.
gain of function
, loss of function
, neomorphic
, unaltered function
, other
Muellers Morph terms: https://en.wikipedia.org/wiki/Muller%27s_morphs
Amorph
, Hypomorph
). Hypermorph
, Antimorph
, Neomorph
, Isomorph
)DDG2P terms: https://www.clinicalgenome.org/site/assets/files/2757/fitzpatrick_ddg2p.pdf
loss of function
, missense in frame
, dominant negative
, activating
, increased dosage
, cis-regulatory promoter mutation
, uncertain
Wormbase allele functional effect terms:
Also of relevance: the 'Protein Function' section on p 7 of the ENIGMA article here: https://jmg.bmj.com/content/56/6/347.full
NextProt: https://www.nextprot.org/entry/NX_P16422/phenotypes
gains localization in endoplasmic reticulum
, decreases protein abundance
Uniprot: https://www.uniprot.org/uniprot/P38398
alters protein stability and abolishes ACACA and BRIP1 binding
.ClinGen: http://dataexchange.clinicalgenome.org/interpretation/entities/AlleleFunctionalImpactStatement.html
desensitized Ca2+ binding to the thin filament
reduced Ca2 sensitivity of activation
the mutation lowered the Ca2+ affinity of the reconstituted thin filaments
Functionally Damaging
abnormal/deceased ERK activation
unchanged from reference
Elements to capture in a statement model: (based on notes from initial requirements work here)
The statement semantics here seem fairly simple, and map cleanly to an ACM-based model as follows:
Issues/Questions:
Relevant discussion on https://github.com/griffithlab/civic-docs/issues/46#issuecomment-612122429. In short, this model is a subset of the functional evidence statements (EIDs) from CIViC, though it excludes the disease
field (which will, going forward, always be set to "cancer"). Since there is (or more precisely, will be) no variability in the value set for that attribute, I think it is safe to model functional evidence from CIViC under the proposed Experimental Functional Impact Annotation.
We will initially proceed with our initial decision to split 'Predicted' from 'Experimental' Functional impact annotations - and model these as separate VA types. Our rationale was that:
The proposals/notes below are derived from the initial requirements work for this VA type here.
Definition: a statement about the impact of a variant on gene product function, as supported by experimental evidence.
Scope/Comments: